Yasuo Uchiyama Selected Research

Synucleins

1/2022	Lack of Cathepsin D in the central nervous system results in microglia and astrocyte activation and the accumulation of proteinopathy-related proteins.
1/2021	Homeostatic p62 levels and inclusion body formation in CHCHD2 knockout mice.
12/2018	Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor dysfunction in aged mice.
10/2012	Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue.
11/2008	Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yasuo Uchiyama Research Topics

Disease

8	Neuronal Ceroid-Lipofuscinoses (Neuronal Ceroid Lipofuscinosis) 01/2022 - 06/2002
8	Parkinson Disease (Parkinson's Disease) 01/2021 - 06/2004
7	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2022 - 06/2006
7	Neoplasms (Cancer) 03/2015 - 10/2005
5	Infections 02/2021 - 01/2005
5	Hyperglycemia 01/2020 - 01/2010
5	Lysosomal Storage Diseases (Lysosomal Storage Disease) 06/2015 - 12/2002
4	Inflammation (Inflammations) 01/2022 - 03/2007
4	Body Weight (Weight, Body) 01/2020 - 02/2009
4	Brain Injuries (Brain Injury) 01/2016 - 01/2004
4	Type 2 Diabetes Mellitus (MODY) 08/2014 - 01/2005
4	Alzheimer Disease (Alzheimer's Disease) 07/2010 - 06/2004
3	Ischemia 01/2016 - 01/2004
3	Starvation 06/2006 - 01/2005
2	Choroidal Neovascularization 03/2021 - 05/2010
2	Chronic Pancreatitis 01/2021 - 11/2016
2	Neuroblastoma 01/2020 - 04/2003
2	Hypertension (High Blood Pressure) 01/2020 - 12/2002
2	Hypertrophy 01/2020 - 01/2011
2	Brain Edema (Cerebral Edema) 01/2018 - 01/2004
2	Infarction (Infarctions) 01/2018 - 04/2006
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2018 - 01/2004
2	Stroke (Strokes) 01/2018 - 02/2009
2	Hepatitis 01/2017 - 12/2012
2	Juvenile Amyotrophic Lateral Sclerosis 2 01/2016 - 03/2010
2	Peptic Esophagitis (Reflux Esophagitis) 09/2014 - 05/2011
2	Mitochondrial Diseases (Mitochondrial Disease) 09/2014 - 10/2012
2	Parkinsonian Disorders (Parkinsonism) 05/2013 - 01/2007
2	Gliosis 12/2012 - 04/2006
2	Glucose Intolerance 11/2009 - 01/2005
2	Atrophy 11/2008 - 02/2003
1	Proteostasis Deficiencies 01/2022
1	Corneal Neovascularization 03/2021
1	Severe Fever with Thrombocytopenia Syndrome 02/2021
1	Virus Diseases (Viral Diseases) 02/2021
1	Vision Disorders (Hemeralopia) 12/2020
1	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 10/2020
1	Obesity 01/2020
1	Insulin Resistance 01/2020
1	Fatty Liver 01/2020
1	Non-alcoholic Fatty Liver Disease 01/2020
1	Acute Kidney Injury (Acute Renal Failure) 04/2019
1	Reperfusion Injury 04/2019
1	Dermatitis 01/2019
1	MYD88 Deficiency 12/2018
1	Disease Progression 12/2018

Drug/Important Bio-Agent (IBA)

20	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2002
11	Cathepsin DIBA 01/2022 - 02/2003
6	Peptide Hydrolases (Proteases)FDA Link 01/2022 - 06/2004
5	SynucleinsIBA 01/2022 - 11/2008
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2017 - 03/2007
3	EnzymesIBA 06/2015 - 06/2004
3	Transcription Factors (Transcription Factor)IBA 01/2010 - 05/2002
2	Cathepsin BIBA 01/2021 - 08/2010
2	Pharmaceutical PreparationsIBA 01/2020 - 12/2002
2	Leptin ReceptorsIBA 01/2020 - 01/2010
2	AntioxidantsIBA 01/2020 - 01/2016
2	LeptinIBA 01/2020 - 11/2009
2	Cysteine (L-Cysteine)FDA Link 01/2020 - 08/2010
2	InterferonsIBA 12/2018 - 12/2012
2	Toll-Like Receptors (Toll-Like Receptor)IBA 12/2018 - 01/2016
2	LipofuscinIBA 12/2016 - 09/2007
2	Kazal Pancreatic Trypsin InhibitorIBA 11/2016 - 01/2014
2	Hyaluronic Acid (Hyaluronan)IBA 01/2016 - 05/2002
2	DNA (Deoxyribonucleic Acid)IBA 03/2015 - 08/2003
2	CathepsinsIBA 09/2014 - 01/2009
2	Mechanistic Target of Rapamycin Complex 1IBA 09/2014 - 01/2011
2	Glucose (Dextrose)FDA LinkGeneric 04/2014 - 01/2005
2	Insulin (Novolin)FDA Link 04/2014 - 01/2011
2	ResveratrolIBA 01/2013 - 10/2011
2	Proteasome Endopeptidase Complex (Proteasome)IBA 12/2012 - 06/2006
2	Indicators and Reagents (Reagents)IBA 05/2011 - 03/2007
2	Cathepsin LIBA 05/2010 - 12/2002
2	Retinaldehyde (Retinal)IBA 05/2010 - 02/2003
2	CeroidIBA 05/2007 - 02/2007
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 04/2006 - 01/2004
2	Amyloid beta-PeptidesIBA 10/2005 - 06/2004
2	Amino Acids FDA Link 05/2005 - 01/2005
1	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 01/2022
1	tau Proteins (tau Protein)IBA 01/2022
1	3,4-dihydroxyphenylpropionic acidIBA 02/2021
1	3,4-Dihydroxyphenylacetic AcidIBA 02/2021
1	Antiviral Agents (Antivirals)IBA 02/2021
1	EstersIBA 02/2021
1	caffeic acidIBA 02/2021
1	protocatechuic acidIBA 02/2021
1	catechol (pyrocatechol)IBA 02/2021
1	oxidized low density lipoproteinIBA 12/2020
1	Lysosomal Membrane ProteinsIBA 10/2020
1	ProgranulinsIBA 10/2020
1	SaposinsIBA 01/2020
1	Guanabenz (BR 750)FDA Link 01/2020
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2020
1	Triglycerides (Triacylglycerol)IBA 01/2020
1	IceIBA 01/2019
1	Myeloid Differentiation Factor 88IBA 12/2018

Therapy/Procedure

2	Transplantation 03/2008 - 06/2004
1	Lasers (Laser) 03/2021
1	Sutures (Suture) 03/2021
1	Oral Administration 01/2020